Curative Effect And Safety Observation Of 0.03% Tacrolimus Ointment In The Treatment Of Facial Plaque Psoriasis

Objective: Psoriasis is an immunological disease with T-cell abnormalities, as the feature of Excessive proliferation of epidermis,parakeratosis,dermal lymphocytic infiltrate.It is a very common chronic relapsing inflammatory disease in clinic.The most common form,and the form for which most treatments are tested,is plaque-type psoriasis,whose incidence of face finds an increasing trend, influencing the quality of life and health of the patients. Tacrolimus is a local immunomodulator,not only inhibit T-cell activation,but also has the potential anti- inflammatory effects. Clinical studies have confirmed that topical application of tacrolimus ointment is safe and the side effects such as systemic immunosuppression are minimal if compared with hormone drugs. After topical application of tacrolimus ointment, the systemic absorption is too slight to cause the systemic immunosuppression. Therefore it is remotely possible to lead to systemic side effects. The data show that long-term treatment of tacrolimus ointment can not cause the skin atrophy, but accelerate the collagen synthesis,and more,reverse the skin atrophy caused by any medication. Topical tacrolimus may be a better choice for the treatment of plaque-type psoriasis. At the beginning of the 1990s, tacrolimus was widely used on psoriasis and the therapeutic effect was very apparent in foreign countries. At the same time, there were the reports of the success in facial plaque psoriasis。But the domestic reports about the treatment of tacrolimus ointment on facial plaque psoriasis are hard to found. This study is to observe the effect and safety of 0.03%tacrolimus ointment in the treatment of facial plaque psoriasis. Methods: Twenty-two patients with facial plaque psoriasis are participated in this study. They were treated with 0.03%tacrolimus ointment. 0.03%Tacrolimus ointment was applied twice a day and lasted for 8 weeks.The curative efficacy was assessed by the change of therapeutic index and adverse events were recorded.We analyze difference of experimental results with SPSS11.5 software.Results:①.After 4 weeks treatment, 15 cases were markedly improved, 7 cases were improved ,with the total effective rate of 83.9%. After 8 weeks treatment,all the 22 cases were markedly improved with the total effective rate of 100%.②.During the course of medication, there were only 2 patients who experienced adverse events such as minor local irritation,which occurred on within the first 3 days of treatment. However,symptoms of irritation were disappeared even no treatment offered. Systemic side effects were not found before and after treatment.Conclusion: 0.03%tacrolimus ointment is effective and safe in the treatment,and worth to be recommended in clinical application.